{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06260514",
            "orgStudyIdInfo": {
                "id": "APR-1051-001"
            },
            "organization": {
                "fullName": "Aprea Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of APR-1051 in Patients With Advanced Solid Tumors",
            "officialTitle": "A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors",
            "acronym": "ACESOT-1051",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-apr-in-patients-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-18",
            "studyFirstSubmitQcDate": "2024-02-14",
            "studyFirstPostDateStruct": {
                "date": "2024-02-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Aprea Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 79,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "APR-1051",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Escalation based on BOIN Design",
                    "interventionNames": [
                        "Drug: APR-1051"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "APR-1051",
                    "description": "WEE1 Inhibitor",
                    "armGroupLabels": [
                        "APR-1051"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Treatment-related adverse events",
                    "description": "* Part 1 dose escalation: Incidence of adverse Events (AE), serious AEs (SAE), treatment-related AEs, AEs that would qualify as a dose-limiting toxicity (DLT), changes in clinical laboratory values, vital signs, ECG, ECHO\n* Part 1 dose escalation: Severity of adverse Events (AE), serious AEs (SAE), treatment-related AEs, and changes in clinical laboratory values, vital signs, ECG, ECHO according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0",
                    "timeFrame": "Day 1 to 28, each cycle is 28 days"
                },
                {
                    "measure": "Recommended dose of APR-1051",
                    "description": "\u2022Part 1 dose escalation: Recommended Phase 2 Dose (RP2D) of APR-1051 monotherapy \\[Time frame: Day 1 through to start of dose expansion phase\\]. The RP2D of will be determined based on review of safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy data",
                    "timeFrame": "Day 1 to 28, each cycle is 28 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics: Cmax/Cmin of APR-1051",
                    "description": "Plasma concentration of APR-1051: maximum (Cmax), minimum (Cmin)",
                    "timeFrame": "Day 1 to 112"
                },
                {
                    "measure": "Pharmacokinetics: Tmax of APR-1051",
                    "description": "Time to peak plasma concentration of APR-1051 (Tmax)",
                    "timeFrame": "Day 1 to 112"
                },
                {
                    "measure": "Pharmacokinetics: AUC of APR-1051",
                    "description": "Area under plasma versus time curve (AUC) of APR-1051 max)",
                    "timeFrame": "Day 1 to 112"
                },
                {
                    "measure": "Pharmacokinetics: t1/2 of APR-1051",
                    "description": "Half-life of APR-1051 (t1/2)",
                    "timeFrame": "Day 1 to 112"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* Diagnosis of advanced/metastatic solid tumor\n* Measurable or evaluable disease per RECIST version 1.1 (radiographic disease progression per PCWG3 criteria for patients with mCRPC)\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1 or Karnofsky Performance Status (KPS) \u2265 70%\n* Patients must have recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade \u2264 2 neuropathy, alopecia, or skin pigmentation\n* Adequate bone marrow and organ function\n* Women of child-bearing potential (WOCBP) or men of child-fathering potential must agree to use adequate contraception prior to study entry\n\nExclusion Criteria:\n\n* Patient has had prior systemic anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy) within 3 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) or at least 5 half-lives (whichever is shorter, but no less than 2 weeks) prior to Day 1\n* Prior radiation therapy at the target lesion unless there is evidence of disease progression. If patient has had prior radiation therapy for disease progression, see Exclusion Criterion 1 for allowed interval between radiotherapy and Day 1 and recovery of AEs\n* Treatment with any investigational agent administered within 30 days or 5 half-lives, whichever is shorter, before the first dose of APR-1051\n* Major surgery within 21 days prior to Day 1\n* Concomitant treatment with other anti-cancer therapy, including chemotherapy, immunotherapy, biological therapy, radiation therapy (except palliative local radiation therapy), or other novel anti-cancer agents. Note: endocrine therapy for breast and prostate cancer is allowed along with agents to treat or prevent skeletal related events (zoledronic acid, pamidronate, denosumab)\n* Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Crystal L Miller, RN BSN",
                    "role": "CONTACT",
                    "phone": "1-617-463-9385",
                    "email": "crystal.miller@aprea.com"
                }
            ],
            "locations": [
                {
                    "facility": "MD Anderson Cancer Center (MDACC)",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jessica Rhudy",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "713-745-5474",
                            "email": "jrhudy@mdanderson.org"
                        },
                        {
                            "name": "Timothy Yap, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology -Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rebecca Popiel",
                            "role": "CONTACT",
                            "phone": "972-893-8800",
                            "email": "rpopiel@nextoncology.com"
                        },
                        {
                            "name": "Naga Cheedella, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "NEXT Oncology -San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jordan Georg",
                            "role": "CONTACT",
                            "phone": "210-580-9500",
                            "email": "jgeorg@nextoncology.com"
                        },
                        {
                            "name": "David Sommerhalder, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}